Radium-223 behandling af knoglemetastaser ved kastrationsrefraktaer prostatacancer
Engelsk titel: Radium-223 treatment of bone metastases from castration-resistant prostate cancer
Läs online
Författare:
Mortensen, Jann
;
Höjgaard, Liselotte
Email: liselotte.hoejgaard@rh.regionh.dk
Språk: Dan
Antal referenser: 24
Dokumenttyp:
Översikt
UI-nummer: 14097249
Sammanfattning
The alpha emitter Radium-223 (223Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in
alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symptoms. Intravenously administered 223Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-
patients.